Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
ASCO 2025 – Astra seeks a new SERD paradigm
But camizestrant’s use could depend on uptake of monitoring – for now.
ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
